AKT1 and cancer: However, HIV protease inhibitors, a class of antiretrovirals that are often included in cART regimens used to treat HIV-positive (HIV+) pregnant women, were shown to decrease VEGF production and to inhibit angiogenesis in cancer cell lines and mouse cancer models, in part by impeding PI3K and Akt activation26–31.